Citigroup Maintains Buy on Exact Sciences, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly has maintained a Buy rating on Exact Sciences (NASDAQ:EXAS) but lowered the price target from $100 to $80.

May 09, 2024 | 5:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup maintains a Buy rating on Exact Sciences but lowers the price target from $100 to $80.
While the maintenance of a Buy rating suggests continued confidence in the company's fundamentals and growth potential, the reduction in the price target could reflect adjustments in market conditions or expectations for the company's future performance. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the new target.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100